Ascendis Pharma (ASND) PT Lowered to $326 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- What the Democratic sweep in the midterms means for markets
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Price: $250.17 --0%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Wells Fargo analyst Chris M. Carey lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $326.00 (from $330.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Arista Networks (ANET) PT Raised to $240 at Truist Securities
- Thinkific Labs Inc (THNC:CN) PT Raised to Cdn$2.50 at BMO Capital
- Freshworks Inc (FRSH) PT Raised to $17 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
